All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

What are the main improvements in next-generation CAR T-cell products?

Featured:

Ben DermanBen Derman

Jan 3, 2023

Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory MM


During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Benjamin Derman, University of Chicago, Chicago, US. We asked, What are the main improvements in next-generation chimeric antigen receptor (CAR) T-cell products?

What are the main improvements in next-generation CAR T-cell products?

In this video, Derman considers multiple abstracts13 presented at ASH 2022 on studies that aim to improve CAR T-cell products, including the development of CAR T-cell therapies that can interact simultaneously with multiple targets, such as BCMA and CD19. Derman also discusses the possibility of reducing turnaround times by optimizing the manufacturing process, as well as developing CAR T‑cell products that can interact with new targets such as GPRC5D. Improvements in the persistence and immune tolerance of CAR T-cell therapies and initiating therapy in earlier lines are also considered.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

Your opinion matters

Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?